NCT02239211View on ClinicalTrials.gov

A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

September 8, 2015

Primary Completion Date

October 23, 2018

Study Completion Date

October 23, 2018

Conditions
Primary Sclerosing Cholangitis
Interventions
DRUG

BTT1023

IV (in the vein) Investigational Medicinal Product (IMP)

Trial Locations (6)

NG7 2UH

Queens Medical Centre, Nottingham

B15 2TH

University Hospitals Birmingham NHS Foundation Trust, Birmingham

Unknown

Addenbrooke's Hospital, Cambridge

Royal Free Hospital, London

Royal Victoria Infirmary, Newcastle

John Radcliffe Hospital, Oxford

Sponsors

Collaborators (1)

Biotie Therapies Corp.
All Listed Sponsors
collaborator

Biotie Therapies Corp.

INDUSTRY

collaborator

University Hospital Birmingham

OTHER

collaborator

National Institute for Health Research, United Kingdom

OTHER_GOV

lead

University of Birmingham

OTHER

NCT02239211 - A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis | Biotech Hunter | Biotech Hunter